Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · mng-umap@100

MNG349

—

31042c99-c226-5ef6-9310-9f38c699e5dd

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • ANGIOGENESIS+0.474
  • ESTROGEN_RESPONSE_EARLY+0.468
  • APICAL_SURFACE+0.454
  • ESTROGEN_RESPONSE_LATE+0.431
  • TNFA_SIGNALING_VIA_NFKB+0.427
  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.405
  • COAGULATION+0.390
  • HYPOXIA+0.386
  • XENOBIOTIC_METABOLISM+0.355
  • TGF_BETA_SIGNALING+0.354

Top 10 suppressed

  • MYC_TARGETS_V2-0.486
  • MYC_TARGETS_V1-0.380
  • WNT_BETA_CATENIN_SIGNALING-0.350
  • OXIDATIVE_PHOSPHORYLATION-0.306
  • E2F_TARGETS-0.301
  • G2M_CHECKPOINT-0.296
  • DNA_REPAIR-0.276
  • INTERFERON_ALPHA_RESPONSE-0.236
  • NOTCH_SIGNALING-0.179
  • MITOTIC_SPINDLE-0.132

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1SRR8518353
breast-umap@18
—F0.890
2MNG1171
mng-umap@100
——0.876
3TCGA-22-4605-01A-21R-2125-07
lung-landscapes@6
—cohortSQ10.869
4MNG657
mng-umap@100
——0.866
5MNG350
mng-umap@100
——0.858
6TCGA-AN-A03X-01A-21R-A00Z-07
breast-umap@18
—A0.857
7SRR8613813
breast-umap@18
—D0.852
8MNG1284
mng-umap@100
——0.843
9TCGA-A2-A0EO-01A-11R-A034-07
breast-umap@18
—A0.843
10SRR8613755
breast-umap@18
—F0.835

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 37 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
ANGIOGENESIS0.474Remibrutinib— uncovered
ESTROGEN_RESPONSE_EARLY0.468Inavolisib— uncovered
APICAL_SURFACE0.454Temsirolimus— uncovered
ESTROGEN_RESPONSE_LATE0.431Idelalisib— uncovered
TNFA_SIGNALING_VIA_NFKB0.427Inavolisib— uncovered
EPITHELIAL_MESENCHYMAL_TRANSITION0.405Inavolisib— uncovered
COAGULATION0.390Binimetinib— uncovered
HYPOXIA0.386Idelalisib— uncovered
XENOBIOTIC_METABOLISM0.355Inavolisib— uncovered
TGF_BETA_SIGNALING0.354Inavolisib— uncovered
PEROXISOME0.346Idelalisib— uncovered
MYOGENESIS0.344Inavolisib— uncovered
BILE_ACID_METABOLISM0.282Inavolisib— uncovered
P53_PATHWAY0.281Idelalisib— uncovered
PANCREAS_BETA_CELLS0.270Cobimetinib— uncovered
APOPTOSIS0.269Idelalisib— uncovered
HEDGEHOG_SIGNALING0.234Inavolisib— uncovered
KRAS_SIGNALING_UP0.234Inavolisib— uncovered
ANDROGEN_RESPONSE0.218Inavolisib— uncovered
PROTEIN_SECRETION0.210Remibrutinib— uncovered